Clinical Trial Update: Correction of Psoriatic T Cell Signatures by Deucravacitinib [Phase 4]

View source ↗

Summary

Phase 4 trial investigating whether deucravacitinib can correct psoriatic T cell signatures in psoriasis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Psoriasis Vulgaris | Phase 4 | Status: RECRUITING